echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Antibiotics: the Roches are back on fire!

    Antibiotics: the Roches are back on fire!

    • Last Update: 2014-03-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: e-medicine Facebook 2014-03-03 at the end of February 2014, Roche and discuva limited, University of Cambridge, UK reached a cooperation agreement to jointly develop a new antibiotic treatment for severe infections caused by resistant bacteria Discuva will provide an antimicrobial target identification platform (satin technology platform), Roche will pay a down payment of 16 million US dollars, and promise 1.75 per product Billion dollars in mileage This is the second transaction launched by Roche in the field of antibiotics in four months: in November 2013, Roche reached a global exclusive license agreement with polyphor pharmaceutical in Switzerland to develop and commercialize the experimental macrocyclic antibiotic pol7080, for which Roche will pay up to CHF 500 million (US $548 million) (see "Roche and polyphor reached an agreement on antibiotic development of US $550 million" which is well known in the industry 15 years ago, Roche took the lead in withdrawing from the research and development of antimicrobial drugs due to the declining returns in the field of antibiotics Then BMS, Lilly, Abbott and Bayer followed suit Pfizer also shut down the research and development of antibacterial drugs in 2011 But now, considering the high incidence of global infection and the few product lines to deal with, Roche has re killed this field through multiple transactions and multiple development plans And other large pharmaceutical companies have returned to the antibiotics field after several years AstraZeneca is one of the few companies that has not given up on antimicrobial research and development In January 2014, AZ reached a cooperation agreement with FOB synthesis to combine the β - lactamase inhibitor of AstraZeneca and carbapenem antibiotics (fsi-1671, fsi-1686) of FOB synthesis to overcome the resistance of Gram-negative bacteria such as Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa Sanofi quit the research and development of antibiotics in 2004 Ten years later, natural product center of excellence was jointly established with Fraunhofer Gesellschaft in January 2014 to promote the discovery and development of new antibiotics This article is compiled according to the article on the FierceBiotech website, and QXI also contributes to this article  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.